Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 13/20 | 0.71 |
| ▸ | SLC6A3 | Q01959 | 13/20 | 0.71 |
| ▸ | SLC6A2 | P23975 | 11/20 | 0.71 |
| ▸ | CYP2D6 | P10635 | 10/20 | 0.71 |
| ▸ | KCNH2 | Q12809 | 10/20 | 0.71 |
| ▸ | CYP1A1 | P04798 | 7/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 7/20 | 0.71 |
| ▸ | CYP2C19 | P33261 | 6/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 6/20 | 0.71 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.71 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14986263 | 0.97 | SLC6A4 (0.73) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL10052470 | 0.96 | SLC6A4 (0.71) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL14986257 | 0.88 | SLC6A3 (0.59) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL14986256 | 0.84 | SLC6A4 (0.55) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL19749346 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL2471765 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13272946 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL13273208 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL2473828 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 | |
| SCHEMBL14889441 | 0.83 | SLC6A4 (1.00) | SLC6A4SLC6A3SLC6A2CYP2D6KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SUNOVION PHARMACEUTICAL INC. (US) | 2013-05-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137744-A1 | PYRROLIDINE TRIPLE REUPTAKE INHIBITORS | SLC18A2, SLC6A2, SLC6A3 | SLC6A4 4/4885SLC6A3 3/4885SLC6A2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.